Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Depreciation & Amortization (CF) (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $38.4 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 2.24% to $38.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $151.8 million through Dec 2025, up 7.76% year-over-year, with the annual reading at $151.8 million for FY2025, 7.76% up from the prior year.
  • Depreciation & Amortization (CF) hit $38.4 million in Q4 2025 for Integra Lifesciences Holdings, roughly flat from $38.5 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $38.5 million in Q3 2025 to a low of $29.2 million in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $32.7 million across 5 years, with a median of $30.8 million in 2021.
  • Biggest five-year swings in Depreciation & Amortization (CF): fell 4.07% in 2022 and later increased 21.66% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $30.7 million in 2021, then fell by 4.07% to $29.5 million in 2022, then increased by 5.05% to $31.0 million in 2023, then rose by 21.31% to $37.6 million in 2024, then grew by 2.24% to $38.4 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for IART at $38.4 million in Q4 2025, $38.5 million in Q3 2025, and $37.7 million in Q2 2025.